To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT01501435
- Locations
- 🇰🇷
Yonsei university severance hospital, Seoul, Korea, Republic of
Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CJ Amlodipine/Valsartan 10/160mgDrug: Novartis Exforge 10/160mg
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT01494727
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 in Healthy Male Subjects
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 86
- Registration Number
- NCT01489774
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT01473173
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01380873
A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 187
- Registration Number
- NCT01370707
- Locations
- 🇰🇷
Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Bundang, Korea, Republic of
🇰🇷Chonbuk National University Hospital, Chonju, Korea, Republic of
A Pharmacokinetic Study of CJ30001 and HKB0701/SLM0807 in Healthy Subject
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01370681
Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy
Phase 4
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: Xarlin (Levocetirizine)Drug: Cosalin (Petasites hybridus CO2 extract)
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT01062139
A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT01039896
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2009-08-11
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT00956098
- Locations
- 🇰🇷
The Catholic University of Korea Holy Family Hospital, Sosa-Dong, Wonmi-Gu, Kyungki-Do, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul St. Mary's Hospital, Banpo-Dong, Seocho-Gu, Seoul, Korea, Republic of